Haemonetics Corp (HAE) Stock Price & Analysis
Haemonetics Corp (HAE) rose 0.07% to USD 102.92 as of September 8, 2026 at 12:00 UTC, according to Nexqual real-time market data.
HAE last closed at USD 102.92; the session ranged USD 101.51–103.57 on volume of 423,177 shares. Market capitalization is —, with a 52-week range of USD 47.32–109.57 (NYQ). Source: Nexqual, September 8, 2026 at 12:00 UTC.
Key Statistics (as of September 8, 2026 at 12:00 UTC)
| Price | USD 102.92 |
|---|---|
| Change | ▲ 0.07% (up) |
| Previous Close | USD 102.92 |
| Open | USD 102.92 |
| Day Range | USD 101.51 – 103.57 |
| 52-Week Range | USD 47.32 – 109.57 |
| Volume | 423,177 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (HAE)
Nexqual's technical model rates HAE "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 12:00 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 66.61 (neutral) |
| vs SMA50 | Above (USD 87.73) |
| MACD | 4.85 (positive) |
From Haemonetics Corp's Latest SEC 10-K Filing (filed 2026-05-20)
Key Strengths & Strategy (as disclosed to the SEC)
- During fiscal 2026 we announced FDA clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology, which represents the next generation of our proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.
- Food and Drug Administration ("FDA") 510(k) clearance for our NexSys PCS with proprietary Persona ® technology.
- In fiscal 2024, we received FDA clearance for advancements to NexSys PCS including a new plasma collection bowl and new Express ® Plus technology engineered to reduce procedure time.
- Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.
Partnerships
- In the U.S., allegations of such wrongful conduct could also result in a corporate integrity agreement with the U.S. government that imposes significant administrative obligations and costs. 11 Table of Contents Requirements Outside the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICUI | ICU Medical, Inc. | USD 167.58 | ▼ 1.34% |
| CNMD | CONMED Corporation | USD 49.32 | ▼ 0.22% |
| IART | Integra LifeSciences Holdings C | USD 16.72 | ▼ 0.54% |
| MMSI | Merit Medical Systems, Inc. | USD 89.6 | ▼ 0.59% |
| ITGR | Integer Holdings Corporation | USD 126.5 | ▲ 0.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:00 UTC. This page is informational and not investment advice.